创新医疗(002173) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥204,206,456.23, representing a 19.22% increase compared to ¥171,290,921.92 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥2,159,886.00, an improvement of 84.83% from a loss of ¥14,238,149.54 in the previous year[5] - The net cash flow from operating activities was ¥12,372,882.62, a significant increase of 117.01% compared to a negative cash flow of ¥72,743,214.00 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 204,206,456.23, an increase of 19.2% compared to CNY 171,290,921.92 in Q1 2022[16] - Net loss for Q1 2023 was CNY 2,096,068.75, a significant improvement from a net loss of CNY 14,211,186.74 in Q1 2022[16] - Cash inflow from operating activities was CNY 222,244,830.87, compared to CNY 133,976,301.93 in the previous year, marking a growth of 66.3%[18] - Basic and diluted earnings per share for Q1 2023 were both CNY -0.0048, an improvement from CNY -0.0320 in Q1 2022[17] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,327,789,036.86, a slight decrease of 0.51% from ¥2,339,662,759.53 at the end of the previous year[5] - Total liabilities decreased to CNY 424,636,503.68 from CNY 434,414,157.60 year-over-year, a reduction of 2%[16] - Total equity attributable to shareholders of the parent company was CNY 1,902,153,166.88, slightly down from CNY 1,904,313,052.88[16] - The company reported a total of ¥1,556,083,863.78 in non-current assets, down from ¥1,568,014,889.21[14] Cash Flow - The company's cash and cash equivalents at the end of the period amount to ¥642,346,295.33, down from ¥658,484,959.64 at the beginning of the year[14] - The net cash flow from operating activities for Q1 2023 was $12,372,882.62, a significant improvement compared to a net outflow of $72,743,214.00 in Q1 2022[19] - Total cash outflow from operating activities amounted to $209,871,948.25, slightly up from $206,719,515.93 in the previous year[19] - The net cash flow from investing activities was -$22,266,188.74, worsening from -$9,829,759.24 in Q1 2022[19] - Cash and cash equivalents at the end of Q1 2023 stood at $642,379,270.35, compared to $132,404,379.55 at the end of Q1 2022[19] - The company reported a total cash outflow from financing activities of $6,065,486.72, an improvement from $10,733,492.80 in the same quarter last year[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 32,942[10] - The largest shareholder, Chen Xiaying, holds 17.13% of shares, totaling 77,616,997 shares, with 3,700,000 shares pledged[10] - The top ten shareholders include several investment funds, indicating a diverse ownership structure[11] - The company has a total of 77,616,997 unrestricted shares held by its largest shareholder, Chen Xiaying[11] Operational Insights - Accounts receivable increased by 33.28% to ¥68,720,668.89, primarily due to increased revenue from subsidiary hospitals[7] - Prepayments surged by 488,134.75% to ¥29,294,085.13, mainly due to a policy adjustment that led to a prepayment of ¥29.25 million from medical insurance[7] - Sales expenses rose by 38.61% to ¥3,075,618.11, attributed to increased marketing efforts in health check services by a subsidiary[7] - The company reported a significant increase in operating income, with cash received from sales and services rising by 65.98% to ¥215,860,854.82[8] - The company received government subsidies amounting to ¥270,623.70 during the reporting period[6] Future Outlook - The company plans to continue expanding its market presence and enhancing its service offerings in the healthcare sector[5] - The company continues to explore market expansion opportunities and new product development strategies to enhance future growth prospects[16] - The company has not received the performance compensation of 4,485,506 shares from Kanghan Investment as of now, which adds uncertainty to future financials[12] - The company is actively taking legal measures to recover the performance compensation owed[12] Miscellaneous - The first quarter report was not audited, which may affect the reliability of the financial data presented[20] - Research and development expenses were not explicitly reported, indicating a potential area for future focus and investment[16]